NSCLC, HNSCC, ESCC, HGSOC, cSCC, cancer du sein HER2 négative avancé, Adénocarcinome oesophagien/adénocarci-nome gastro-oesophagien, cancer de la vessie, cancer degestif, cancer du col de l'utérus
Seagen Inc.
I
dernière
SGN-B6A
CHUV
● To evaluate the safety and tolerability of SGN-B6A in subjects with advanced solid tumors
● To identify the maximum tolerated dose (MTD) of SGN-B6A in subjects with advanced solid tumors
● To identify a recommended dose and schedule for SGN-B6A
Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part). Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic option:
Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows:
are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
have no new or enlarging brain metastases, and
are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.